Heart Disease Clinical Trials in Orlando, FL

46 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS	Phase 3	DalCor Pharmaceuticals	<1 mi
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin	Phase 3	AstraZeneca	<1 mi
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System	N/A	Boston Scientific Corporation	<1 mi
Assessment of CCM in HF With Higher Ejection Fraction	N/A	Impulse Dynamics	<1 mi
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE	—	Medtronic Cardiovascular	<1 mi
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System	N/A	Biosense Webster, Inc.	<1 mi
BoxX-NoAF Clinical Trial	N/A	AtriCure, Inc.	<1 mi
Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure	N/A	Analog Device, Inc.	<1 mi
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants	N/A	Nationwide Children's Hospital	<1 mi
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity	Phase 3	Amgen	<1 mi
CCM OPEN HF Registry	—	Impulse Dynamics	<1 mi
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction	Phase 3	Cytokinetics	<1 mi
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease	Phase 3	Alessandro Doria	<1 mi
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy	Phase 2	Novo Nordisk A/S	<1 mi
SELUTION 4 De Novo Small Vessel IDE Trial	N/A	M.A. Med Alliance S.A.	<1 mi
The CONFORM Pivotal Trial	N/A	Conformal Medical, Inc	<1 mi
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension	Phase 2	Retension Pharmaceuticals. Inc.	<1 mi
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)	N/A	Biosense Webster, Inc.	<1 mi
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation	N/A	Arga Medtech SA	<1 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)	Phase 2/3	CSL Behring	<1 mi
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR	N/A	Cardiac Dimensions, Inc.	<1 mi
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment	—	Children's Oncology Group	<1 mi
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma	—	Children's Oncology Group	<1 mi
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure	N/A	BrioHealth Solutions, Inc.	<1 mi
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity	Phase 3	Novo Nordisk A/S	<1 mi
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease	—	Children's Hospital Medical Center, Cincinnati	<1 mi
Tracking Results of Ablations to Combat AF Registry Generation 2	—	AtriCure, Inc.	<1 mi
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders	Phase 3	Ascendis Pharma A/S	<1 mi
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy	Phase 3	Lexicon Pharmaceuticals	<1 mi
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study	N/A	AtaCor Medical, Inc.	<1 mi
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)	N/A	Medtronic Cardiac Ablation Solutions	<1 mi
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk	Phase 3	Eli Lilly and Company	5 mi
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events	Phase 3	Amgen	5 mi
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease	Phase 1	Verve Therapeutics, Inc.	5 mi
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable	Phase 3	Regeneron Pharmaceuticals	5 mi
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart	Phase 3	Boehringer Ingelheim	5 mi
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure	Phase 3	Boehringer Ingelheim	5 mi
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation	Phase 2	Regeneron Pharmaceuticals	5 mi
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)	Phase 2	Pfizer	5 mi
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function	Phase 3	AstraZeneca	9 mi
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)	Phase 3	Anthos Therapeutics, Inc.	9 mi
AngelMed Guardian® System PMA Post Approval Study	—	Angel Medical Systems	24 mi
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation	Phase 3	Johns Hopkins University	42 mi
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF	Phase 3	Tenax Therapeutics, Inc.	42 mi
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)	Phase 3	Novartis Pharmaceuticals	48 mi
Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure	Phase 4	Lakeland Regional Health Systems, Inc.	49 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.